These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 23314137

  • 1. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC, Geisser P.
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [Abstract] [Full Text] [Related]

  • 2. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
    Rottembourg J, Rostoker G.
    Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
    [Abstract] [Full Text] [Related]

  • 3. Update on intravenous iron choices.
    Larson DS, Coyne DW.
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):186-91. PubMed ID: 24401789
    [Abstract] [Full Text] [Related]

  • 4. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 5. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P, Hahn KM.
    MMW Fortschr Med; 2013 Mar 21; 155 Suppl 1():18-24. PubMed ID: 23678667
    [Abstract] [Full Text] [Related]

  • 6. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
    Nephrol Dial Transplant; 2013 Apr 21; 28(4):953-64. PubMed ID: 23222534
    [Abstract] [Full Text] [Related]

  • 7. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol; 2014 Jun 21; 81(6):419-26. PubMed ID: 24691014
    [Abstract] [Full Text] [Related]

  • 8. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
    Toblli JE, Cao G, Giani JF, Dominici FP, Angerosa M.
    Drug Res (Stuttg); 2015 Jul 21; 65(7):354-60. PubMed ID: 25050519
    [Abstract] [Full Text] [Related]

  • 9. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?
    Macdougall IC.
    Curr Med Res Opin; 2010 Feb 21; 26(2):473-82. PubMed ID: 20014980
    [Abstract] [Full Text] [Related]

  • 10. Iron Treatment Strategies in Nondialysis CKD.
    Macdougall IC.
    Semin Nephrol; 2016 Mar 21; 36(2):99-104. PubMed ID: 27236130
    [Abstract] [Full Text] [Related]

  • 11. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.
    Clin J Am Soc Nephrol; 2014 Apr 21; 9(4):705-12. PubMed ID: 24458078
    [Abstract] [Full Text] [Related]

  • 12. Distinct in vitro Complement Activation by Various Intravenous Iron Preparations.
    Hempel JC, Poppelaars F, Gaya da Costa M, Franssen CF, de Vlaam TP, Daha MR, Berger SP, Seelen MA, Gaillard CA.
    Am J Nephrol; 2017 Apr 21; 45(1):49-59. PubMed ID: 27889746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E, Shelly J, Cheng S, Kaakeh Y, Shepler B.
    Ann Pharmacother; 2011 Feb 21; 45(2):241-7. PubMed ID: 21304025
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evolution of iv iron compounds over the last century.
    Macdougall IC.
    J Ren Care; 2009 Dec 21; 35 Suppl 2():8-13. PubMed ID: 19891680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.